Nilgun Tasdemir

Nilgun Tasdemir

Auto-generated profile, based on publicly available information

Nilgun Tasdemir

University of Pittsburgh

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2017 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
ABAmir Bahreini
Amir Bahreini
ZLZheqi Li
Zheqi Li
PWPeilu Wang
Peilu Wang
KLKevin M. Levine
Kevin M. Levine
NTNilgun Tasdemir
Nilgun Tasdemir
SOSteffi Oesterreich
Steffi Oesterreich
Mutations in the estrogen receptor alpha (ERα) 1 gene (ESR1) are frequently detected in ER+ metastatic breast cancer, and there is increasing evidence that these mutations confer endocrine resistance in breast cancer patients with advanced disease. However, their functional role is not well-understood, at least in part due to a lack of ESR1 mutant models. Here, we describe the generation and characterization of genome-edited T47D and MCF7 breast cancer cell lines with the two most common ESR1 mutations, Y537S and D538G. Genome editing was performed using CRISPR and adeno-associated virus (AAV) technologies to knock-in ESR1 mutations into T47D and MCF7 cell lines, respectively. Various techniques were utilized to assess the activity of mutant ER, including transactivation, growth and chromatin-immunoprecipitation (ChIP) assays. The level of endocrine resistance was tested in mutant cells using a number of selective estrogen receptor modulators (SERMs) and degraders (SERDs). RNA sequencing (RNA-seq) was employed to study gene targets of mutant ER. Cells with ESR1 mutations displayed ligand-independent ER activity, and were resistant to several SERMs and SERDs, with cell line and mutation-specific differences with respect to magnitude of effect. The SERD AZ9496 showed increased efficacy compared to other drugs tested. Wild-type and mutant cell co-cultures demonstrated a unique evolution of mutant cells under estrogen deprivation and tamoxifen treatment. Transcriptome analysis confirmed ligand-independent regulation of ERα target genes by mutant ERα, but also identified novel target genes, some of which are involved in metastasis-associated phenotypes. Despite significant overlap in the ligand-independent genes between Y537S and D538G, the number of mutant ERα-target genes shared between the two cell lines was limited, suggesting context-dependent activity of the mutant receptor. Some genes and phenotypes were unique to one mutation within a given cell line, suggesting a mutation-specific effect. Taken together, ESR1 mutations in genome-edited breast cancer cell lines confer ligand-independent growth and endocrine resistance. These biologically relevant models can be used for further mechanistic and translational studies, including context-specific and mutation site-specific analysis of the ESR1 mutations.

1 September 2020 in Endocrinology
Verified
Journal Article
Open access
PDF file
SSSreeja Sreekumar
Sreeja Sreekumar
KLKevin M Levine
Kevin M Levine
MSMatthew Sikora
Matthew Sikora
JCJian Chen
Jian Chen
NTNilgun Tasdemir
Nilgun Tasdemir
SOSteffi Oesterreich
Steffi Oesterreich
Invasive lobular breast carcinoma (ILC) accounts for 10% to 15% of breast cancers diagnosed annually. Evidence suggests that some aspects of endocrine treatment response might differ between invasive ductal carcinoma (IDC) and ILC, and that patients with ILC have worse long-term survival. We analyzed The Cancer Genome Atlas dataset and observed lower levels of ESR1 mRNA (P = 0.002) and ERα protein (P = 0.038) in ER+ ILC (n = 137) compared to IDC (n = 554), and further confirmed the mRNA difference in a local UPMC cohort (ILC, n = 143; IDC, n = 877; P < 0.005). In both datasets, the correlation between ESR1 mRNA and ERα protein was weaker in ILC, suggesting differential post-transcriptional regulation of ERα. In vitro, 17β-estradiol (E2) decreased the rate of degradation and increased the half-life of ERα in ILC cell lines, whereas the opposite was observed in IDC cell lines. Further, E2 failed to induce robust ubiquitination of ERα in ILC cells. To determine the potential clinical relevance of these findings, we evaluated the effect of 2 selective estrogen receptor downregulators (SERDs), ICI 182,780 and AZD9496, on ERα turnover and cell growth. While ICI 182,780 and AZD9496 showed similar effects in IDC cells, in ILC cell lines, AZD9496 was not as effective as ICI 182,780 in decreasing ERα stability and E2-induced proliferation. Furthermore, AZD9496 exhibited partial agonist activity in growth assays in ILC cell lines. Our study provides evidence for a distinct ERα regulation by SERDs in ILC cell lines, and therefore it is important to include ILC models into preclinical and clinical testing of novel SERDs.

23 February 2019 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
EBEmily A. Bossart
Emily A. Bossart
NTNilgun Tasdemir
Nilgun Tasdemir
MSMatthew Sikora
Matthew Sikora
ABAmir Bahreini
Amir Bahreini
KLKevin M. Levine
Kevin M. Levine
SOSteffi Oesterreich
Steffi Oesterreich

17 September 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
AEAshuvinee Elangovan
Ashuvinee Elangovan
EBEmily A. Bossart
Emily A. Bossart
ABAhmed Basudan
Ahmed Basudan
NTNilgun Tasdemir
Nilgun Tasdemir
OSOsama Shiraz Shah
Osama Shiraz Shah
SOSteffi Oesterreich
Steffi Oesterreich
Breast cancer is broadly divided histologically into no special type (NST) and special subtypes, of which invasive lobular carcinoma (ILC) is the most common. ILC is distinguished by discohesive, single-file growth from loss of E-cadherin (CDH1). Few ILC cell lines exist, limiting mechanistic study of this understudied disease. Here we describe WCRC-25, a novel ILC cell line established from a pleural effusion of a patient with metastatic ILC. While WCRC-25 lacks ER expression, it is molecularly defined as luminal with Her2-like features, and shows anchorage-independent growth and haptotactic migration toward Collagen I. Sequencing identified a CDH1 Q706* truncating mutation alongside FOXA1, CTCF, BRCA2 and TP53 mutations shared with the patient's metastases, while copy-number and optical genome mapping revealed structural rearrangements typical of ILC. Transcriptomic AKT-pathway signatures predicted, and cell-based assays confirmed, sensitivity to PI3K/AKT inhibition. WCRC-25 also engrafted and spontaneously metastasized in vivo. WCRC-25 is a valuable new tool for dissecting ILC biology and therapeutic vulnerabilities.

24 January 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
ANAlison M. Nagle
Alison M. Nagle
KLKevin M. Levine
Kevin M. Levine
NTNilgun Tasdemir
Nilgun Tasdemir
JSJulie A. Scott
Julie A. Scott
KBKara Burlbaugh
Kara Burlbaugh
ALAdrian V. Lee
Adrian V. Lee
Purpose: Insulin-like growth factor I (IGF1) signaling regulates breast cancer initiation and progression and associated cancer phenotypes. We previously identified E-cadherin (CDH1) as a repressor of IGF1 signaling and in this study examined how loss of E-cadherin affects IGF1R signaling and response to anti-IGF1R therapies in breast cancer. Experimental Design: Breast cancer cell lines were used to assess how altered E-cadherin levels regulate IGF1R signaling and response to two anti-IGF1R therapies. In situ proximity ligation assay (PLA) was used to define interaction between IGF1R and E-cadherin. TCGA RNA-seq and RPPA data was used to compare IGF1R activation in estrogen receptor positive (ER+) invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) tumors. ER+ ILC cell lines and xenograft tumor explant cultures were used to evaluate efficacy to IGF1R pathway inhibition in combination with endocrine therapy. Results: Diminished functional E-cadherin increased both activation of IGF1R signaling and efficacy to anti-IGF1R therapies. PLA demonstrated a direct endogenous interaction between IGF1R and E-cadherin at points of cell-cell contact. Increased expression of IGF1 ligand and levels of IGF1R phosphorylation were observed in E-cadherin deficient ER+ ILC compared to IDC tumors. IGF1R pathway inhibitors were effective in inhibiting growth in ER+ ILC cell lines and synergized with endocrine therapy and similarly IGF1R inhibition reduced proliferation in ILC tumor explant culture. Conclusions: We provide evidence that loss of E-cadherin hyperactivates the IGF1R pathway and increases sensitivity to IGF1R targeted therapy, thus identifying the IGF1R pathway as a potential novel target in E-cadherin deficient breast cancers. STATEMENT OF SIGNIFICANCE: IGF1R signaling is an attractive therapeutic target in breast cancer due to its regulation of proliferation, migration, and invasion. However, clinical trials targeting IGF1R have largely been unsuccessful due to lack of biomarkers to stratify patients for therapeutic response. In this study, we demonstrate loss of E-cadherin as a potential biomarker for response to anti-IGF1R therapy, and show efficacy of IGF1R inhibition in ER+ ILC in combination with endocrine therapy. Patients with ER+ ILC have poorer long-term outcomes than patients with ER+ IDC and have a propensity for increased late recurrences, highlighting the need for improved therapeutic strategies for this subtype of breast cancer. Here, we credential IGF1R inhibition as a novel therapeutic strategy in combination with endocrine therapy for the treatment of ER+ ILC.

7 February 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
NTNilgun Tasdemir
Nilgun Tasdemir
KDKai Ding
Kai Ding
KLKevin M. Levine
Kevin M. Levine
TDTian Du
Tian Du
EBEmily A. Bossart
Emily A. Bossart
SOSteffi Oesterreich
Steffi Oesterreich
BACKGROUND: Invasive lobular carcinoma (ILC) is a histological subtype of breast cancer with distinct molecular and clinical features from the more common subtype invasive lobular carcinoma (IDC). We have previously shown that human ILC cells lines have a remarkably unique ability to grow in ultra-low attachment (ULA) suspension cultures as compared to IDC cells, the mediators of which remain unknown.METHODS: Using flow cytometry and immunoblotting in human ILC and IDC cell lines, we measured levels of apoptosis and cell proliferation in attached (2D) and suspension (ULA) cultures. siRNA-mediated knockdown and pharmacological inhibitors were utilized to assess the effects of known regulators of anchorage-independence. Reverse Phase Protein Arrays and RNA-Sequencing were performed to identify novel proteomic and transcriptomic mediators of ULA growth in ILC cells.RESULTS: We show that human ILC cell lines exhibit enhanced anoikis resistance and cell proliferation in ULA cultures as compared to IDC cells. Transient restoration of E-cadherin did not impact the 2D or ULA growth of human ILC cell lines, while transient E-cadherin knockdown in IDC cells partially rescued their growth defect in ULA culture. Inhibition of the Rho/ROCK, p120-catenin or YAP/Hippo pathways previously implicated in anoikis resistance did not have a major effect on the ULA growth of ILC cells. Proteomic comparison of ILC and IDC cell lines identified unique induction of PI3K/Akt and p90-RSK pathways in ULA culture in ILC cells. Transcriptional profiling uncovered unique upregulation of the Inhibitors of Differentiation family transcription factors ID1 and ID3 in ILC ULA culture, the knockdown of which diminished anchorage-independent growth. We find that ID1 and ID3 expression is higher in human ILC tumors as compared to IDC and correlated with a worse disease-specific survival uniquely in the ILC cohort.CONCLUSION: Our comprehensive study of 2D and ULA growth in human ILC cell lines revealed anoikis resistance, cell proliferation and novel mediators of anchorage-independence and provides possible mechanistic insights and clinical implications for metastatic dissemination of ILC. High expression in human ILC tumors and association with clinical outcome implicate ID1 and ID3 as novel drivers and therapeutic targets for lobular breast cancer.